Axela has introduced nine plate-based tumour marker assays for stand-alone use or to simplify the transition to automated Dotlab assays.
The tumour-marker assays are available in high performance Elisa format.
These assays, when used in conjunction with Axela's Panelplus biomarker menu (available for the Dotlab system this summer) can transform the speed with which putative biomarkers can be validated.
The following RUO (research use only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP); carcinoembroyonic antigen (CEA); CA125; CA15-3; CA 19-9; PSA; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin (free beta-hCG) and beta-2 Microglobulin (B2MG).
The Panelplus biomarker menu will incorporate the same capture reagents as these Elisa kits, allowing it to facilitate assay validation and simplify multiplexing.
The ability to observe multiple analytes in real-time provides a wider detection range than was previously available.
The Dotlab system offers significant advantages over end-point techniques and allows these self-addressing reagents to be used to create highly targeted and flexible biomarker panels.
Scientists will be able to select from the menu of analytes and incorporate their own proprietary reagents using the Panelplus address kit.
Novel discoveries can be compared directly with markers with known utility without increasing sample-volume requirements.
Axela is extending the versatility of the Dotlab System by providing biomarker assay and validation tools that complement its ability to perform interaction studies, expression monitoring and analysis of cancer autoantibodies.
These new, easy to use, robust Elisas will help researchers quantitate cancer biomarkers in basic and clinical research settings and will be followed by a selection of cardiology and infectious-disease targets.
They are available through VWR Life Science in North America and Axela in Europe.
